Open Access
Subscription Access
Exploring Pharmacological Interventions for Vaginal Cancer: A Comprehensive Overview
Abstract
Vaginally cancer is a rare malignancy that happens in the cells of the vagina and pharmacological interventions play a major role managing vaginal cancer. Cisplatin, a platinum _ based chemotherapy drug, is used in a wide manner regarding the treatment of different types of cancers along with vaginal cancer. Cisplatin performs by interfering with the DNA inside the cancer cells, stopping their capability to divide and grow. 5_ Fluorosis uracil ( 5_ Fu) is an anti metabolite drug that disrupts the synthesis of DNA and RNA, stopping the growth of cancer cells. Trastuzumide ( Herceptin) is a mono clonal antibody that targets the HER 2 protein, which is over expressed in a very few types of vaginally cancers. By inhibiting HER2, trastuzumab stopsvthe growth if cancer cells. Bevacizumab is an anti_ angiogenic drug that stops the formation of new blood vessels in tumors. By stopping the blood supply, it limits the tumors ability to grow and spread. Bevacizumab may be used along with chemotherapy especially for advanced cases. Tamoxifen, an estrogen receptor modulator , interfere with the capability of estrogen, thereby slowing down or stopping the growth of hormone _ sensitive tumors. Pembroluzumab has exhibited promise particularly in certain ctypes of vaginal cancer, specifically those with micro satellite instability, high ( MSI _ H) or mismatch repair deficient ( d MMR) status. Finally it is concluded that while surgical or radiation interventions remain corner stones regarding management of vaginal cancer.
References
Adams TS, Cuello MA. Cancer of the vagina. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:14-21. [PubMed]
Gardner CS, Sunil J, Klopp AH, Devine CE, Sagebiel T, Viswanathan C, Bhosale PR. Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. Br J Radiol. 2015 Aug;88(1052):20150033. [PMC free article] [PubMed]
Ng QJ, Namuduri RP, Yam KL, Lim-Tan SK. Vaginal metastasis presenting as postmenopausal bleeding. Singapore Med J. 2015 Aug;56(8):e134-6. [PMC free article] [PubMed]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. [PubMed]
Kulkarni A, Dogra N, Zigras T. Innovations in the Management of Vaginal Cancer. Curr Oncol. 2022 Apr 27;29(5):3082-3092. [PMC free article] [PubMed]
Siegler E, Segev Y, Mackuli L, Auslender R, Shiner M, Lavie O. Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. Isr Med Assoc J. 2016 May;18(5):286-9. [PubMed]
Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol. 2009 Apr;113(4):917-924. [PubMed]
Haręża DA, Wilczyński JR, Paradowska E. Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins. Int J Mol Sci. 2022 Feb 05;23(3) [PMC free article] [PubMed]
Conlon JL. Diethylstilbestrol: Potential health risks for women exposed in utero and their offspring. JAAPA. 2017 Feb;30(2):49-52. [PubMed]
Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002 Feb;84(2):263-70. [PubMed]
Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998 Sep 01;83(5):1033-40. [PubMed]
Shah CA, Goff BA, Lowe K, Peters WA, Li CI. Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol. 2009 May;113(5):1038-1045. [PMC free article] [PubMed]
Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec;116(6):1358-1365. [PubMed]
Ramzy I, Smout MS, Collins JA. Verrucous carcinoma of the vagina. Am J Clin Pathol. 1976 May;65(5):644-53. [PubMed]
Ghaemmaghami F, Karimi Zarchi M, Ghasemi M. Lower genital tract rhabdomyosarcoma: case series and literature review. Arch Gynecol Obstet. 2008 Jul;278(1):65-9. [PubMed]
Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. Melanoma of the lower genital tract: Prognostic factors and treatment modalities. Gynecol Oncol. 2018 Jul;150(1):180-189. [PubMed]
Udager AM, Frisch NK, Hong LJ, Stasenko M, Johnston CM, Liu JR, Chan MP, Harms PW, Fullen DR, Orsini A, Thomas DG, Lowe L, Patel RM. Gynecologic melanomas: A clinicopathologic and molecular analysis. Gynecol Oncol. 2017 Nov;147(2):351-357. [PubMed]
Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S84-7. [PubMed]
Lee CK, Lin H, Su CF, Kok VC. Primary Vaginal Melanoma With Rhabdoid Features: A Case Report and Literature Review. Int J Gynecol Pathol. 2017 Sep;36(5):499-504. [PubMed]
Shrivastava SB, Agrawal G, Mittal M, Mishra P. Management of Vaginal Cancer. Rev Recent Clin Trials. 2015;10(4):289-97. [PubMed]
Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS, Kidd EA. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes. Gynecol Oncol. 2013 Nov;131(2):380-5. [PubMed]
Matsuo K, Blake EA, Machida H, Mandelbaum RS, Roman LD, Wright JD. Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecol Oncol. 2018 Sep;150(3):501-508. [PMC free article] [PubMed]
Indraccolo U, Baldoni A. A simplified classification for describing colposcopic vaginal patterns. J Low Genit Tract Dis. 2012 Apr;16(2):75-9. [PubMed]
Hansen BT, Campbell S, Nygård M. Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway. BMJ Open. 2018 Feb 23;8(2):e019005. [PMC free article] [PubMed]
Mbuyisa SS, Khumalo TL, Makhathini BS, Moodley J. Prevalance of abnormal vault cytology after hysterectomy for cervical intraepithelial neoplasia, Pietermaritzburg. S Afr Fam Pract (2004). 2022 Mar 31;64(1):e1-e5. [PMC free article] [PubMed]
Egemen D, Perkins RB, Clarke MA, Guido R, Huh W, Saraiya M, Saslow D, Smith R, Unger ER, Garcia F, Wentzensen N, Cheung LC., Enduring Consensus Cervical Cancer Screening and Management Committee. Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available. J Low Genit Tract Dis. 2022 Jul 01;26(3):195-201. [PMC free article] [PubMed]
Kim MK, Lee IH, Lee KH. Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases. J Gynecol Oncol. 2018 Jan;29(1):e6. [PMC free article] [PubMed]
FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009 Apr;105(1):3-4. [PubMed]
Hauth EA, Kimmig R, Forsting M. [Diagnosis of vulval and vaginal neoplasms with magnetic resonance imaging]. Gynakol Geburtshilfliche Rundsch. 2007;47(4):226-35. [PubMed]
Rajaram S, Maheshwari A, Srivastava A. Staging for vaginal cancer. Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):822-32. [PubMed]
Robertson NL, Hricak H, Sonoda Y, Sosa RE, Benz M, Lyons G, Abu-Rustum NR, Sala E, Vargas HA. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. Gynecol Oncol. 2016 Mar;140(3):420-4. [PMC free article] [PubMed]
Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer. 2022 Mar;32(3):344-351. [PMC free article] [PubMed]
Gadducci A, Fabrini MG, Lanfredini N, Sergiampietri C. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol. 2015 Mar;93(3):211-24. [PubMed]
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):19-27. [PMC free article] [PubMed]
Jain V, Sekhon R, Giri S, Bora RR, Batra K, Bajracharya A, Rawal S. Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. Int J Gynecol Cancer. 2016 Jul;26(6):1176-81. [PubMed]
Stein R, Ganeshan D, Gopireddy DR, Chaudhry A, Kumar S, Bande K, Bhosale P, Lall C. Current update on vaginal malignancies. Abdom Radiol (NY). 2021 Nov;46(11):5353-5368. [PubMed]
Rajagopalan MS, Xu KM, Lin JF, Sukumvanich P, Krivak TC, Beriwal S. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol. 2014 Dec;135(3):495-502. [PubMed]
Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. PLoS One. 2013;8(6):e65048. [PMC free article] [PubMed]
Zhou WL, Yue YY. Radiotherapy Plus Chemotherapy Is Associated With Improved Survival Compared to Radiotherapy Alone in Patients With Primary Vaginal Carcinoma: A Retrospective SEER Study. Front Oncol. 2020;10:570933. [PMC free article] [PubMed]
Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Panici PB. Vaginal cancer. Crit Rev Oncol Hematol. 2012 Mar;81(3):286-95. [PubMed]
Dobrică EC, Vâjâitu C, Condrat CE, Crețoiu D, Popa I, Gaspar BS, Suciu N, Crețoiu SM, Varlas VN. Vulvar and Vaginal Melanomas-The Darker Shades of Gynecological Cancers. Biomedicines. 2021 Jun 30;9(7) [PMC free article] [PubMed]
Ng HJ, Aly EH. Vaginal metastases from colorectal cancer. Int J Surg. 2013;11(10):1048-55. [PubMed]
Kirkbride P, Fyles A, Rawlings GA, Manchul L, Levin W, Murphy KJ, Simm J. Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol. 1995 Mar;56(3):435-43. [PubMed]
Chang JH, Jang WI, Kim YB, Kim JH, Kim YS, Kim YS, Park W, Kim J, Yoon WS, Kim JY, Kim HJ. Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). J Gynecol Oncol. 2016 Mar;27(2):e17. [PMC free article] [PubMed]
Kirchheiner K, Smet S, Jürgenliemk-Schulz IM, Haie-Meder C, Chargari C, Lindegaard JC, Fokdal LU, Spampinato S, Schmid MP, Sturdza A, Mahantshetty U, Segedin B, Bruheim K, Rai B, Cooper R, Van der Steen-Banasik E, Wiebe E, Sundset M, van Limbergen E, Villafranca E, Westerveld H, Tan LT, Pötter R, Tanderup K, Nout RA., EMBRACE Collaborative Group. Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. Int J Radiat Oncol Biol Phys. 2022 Feb 01;112(2):400-413. [PubMed]
Refbacks
- There are currently no refbacks.